CN
Search Within
F0778
应用筛选条件
关键词:'F0778'
显示 1-30 共 47 条结果 关于 "F0778" 范围 论文
John M Pellock et al.
Epilepsy research, 71(2-3), 89-101 (2006-08-08)
An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed
Anas I Ghousheh et al.
The Journal of urology, 189(5), 1865-1869 (2012-12-25)
We report 4 cases of felbamate urolithiasis. We identified only 1 prior case report of a felbamate stone. Felbamate is an antiepileptic drug used to treat refractory seizures and has minor side effects when given in recommended doses. We analyzed
J M Pellock
Epilepsia, 40 Suppl 5, S57-S62 (1999-10-26)
Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy. The identification of
M R Domenici et al.
Life sciences, 58(26), PL391-PL396 (1996-05-24)
The effects of the novel anticonvulsant felbamate, which binds to the 5-7 dichlorokynurenic binding sites, were tested towards the CA1 epileptiform activity induced in rat hippocampal slices by kainic acid. The effects of the kynurenic acid derivatives 7-chlorokynurenic acid and
Andrew J Hill et al.
Journal of neuroscience methods, 185(2), 246-256 (2009-10-20)
The acute hippocampal brain slice preparation is an important in vitro screening tool for potential anticonvulsants. Application of 4-aminopyridine (4-AP) or removal of external Mg(2+) ions induces epileptiform bursting in slices which is analogous to electrical brain activity seen in
Angelique M Leone et al.
Chemical research in toxicology, 20(4), 600-608 (2007-03-27)
Felbamate is an antiepileptic drug that is associated with minimal toxicity in preclinical species such as rat and dog but has an unacceptable incidence of serious idiosyncratic reactions in man. Idiosyncratic reactions account for over half of toxicity-related drug failures
Eileen Broomall et al.
Annals of neurology, 76(6), 911-915 (2014-11-05)
Super-refractory status epilepticus is a life-threatening condition. Resistance to benzodiazepine and barbiturate treatment for this disorder is thought to be due to internalization of synaptic γ-aminobutyric acid (GABA)A receptors, and withdrawal of benzodiazepines and barbiturates during treatment often triggers seizure
N W Kleckner et al.
The Journal of pharmacology and experimental therapeutics, 289(2), 886-894 (1999-04-24)
Felbamate is an anticonvulsant used in the treatment of seizures associated with Lennox-Gastaut syndrome and complex partial seizures that are refractory to other medications. Its unique clinical profile is thought to be due to an interaction with N-methyl-D-aspartate (NMDA) receptors
J M Pellock
Drug safety, 21(3), 225-239 (1999-09-16)
Felbamate demonstrates a unique therapeutic profile and often results in seizure control when other agents fail. Its use has been associated with risks for aplastic anaemia and hepatic failure. A number of confounding factors makes the actual incidence rate for
J Chahem et al.
Der Nervenarzt, 78(12), 1407-1412 (2007-07-03)
We retrospectively analysed the anticonvulsant efficacy of add-on treatment with felbamate (FBM), tiagabine (TGB), or sulthiame (STM) in patients with intractable focal and/or secondarily generalised seizures. Forty-one patients (25 men, 16 women, mean age 29 years, mean duration of epilepsy
Jarogniew J Luszczki et al.
Pharmacology, 81(3), 259-265 (2008-02-07)
This study focused on the evaluation of interactions between MRZ 2/576 (8-chloro-4-hydroxy-1-oxo-1,2-dihydropyridazino(4,5-b)quinoline-5-oxide choline salt), an N-methyl-D-aspartate (NMDA) receptor antagonist acting at the NMDA receptor/glycine(B) site and four newer antiepileptic drugs (felbamate, lamotrigine, oxcarbazepine, and topiramate) in the mouse maximal electroshock
H Kearney et al.
Irish medical journal, 102(10), 326-328 (2010-01-30)
Felbamate (FBM) is efficacious in treating patients with refractory epilepsy but was withdrawn due to cases of aplastic anaemia, hepatic failure and five reported deaths. FBM is currently used in specialist centres and is only being used in one Irish
J Pérez-Miranda et al.
Revista de neurologia, 23(124), 1220-1225 (1995-11-01)
The present work is a review of the new anti-epileptic drug felbamate. Felbamate is a dicarbonate with antiepileptic effects in partial attacks and in Lennox-Gastaut syndrome. This new drug is especially interesting since its pharmacological action on test animals would
R Corradetti et al.
Life sciences, 63(13), 1075-1088 (1998-10-08)
Felbamate is a broad spectrum antiepileptic drug recently introduced into clinical practice for controlling seizures in patients affected by Lennox-Gastaut epilepsy, complex partial seizures or otherwise intractable epilepsies. However, the cellular mechanisms by which the drug exerts its anticonvulsant actions
[New antiepileptics in development].
Gerd Dannhardt et al.
Pharmazie in unserer Zeit, 36(4), 306-310 (2007-07-12)
Huai-Ren Chang et al.
Biophysical journal, 93(6), 1981-1992 (2007-05-22)
Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect is chiefly related to gating modification (and thus use-dependent inhibition) rather than pore block of N-methyl-D-aspartate (NMDA) channels at pH 7.4. Using whole-cell recording in rat hippocampal neurons, we examined
Ryan J Hansen et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 878(32), 3432-3436 (2010-11-18)
Felbamate (2-phenyl-1,3-propanediol dicarbamate) is a second generation antiepileptic drug used to treat seizures refractory to other antiepileptic drugs. With approximately 3500 new patients exposed annually, several important pharmacologic interaction questions remain unanswered necessitating the need for rapid and accurate methods
K D Laxer
The Western journal of medicine, 161(3), 309-314 (1994-09-01)
For the first time in 15 years, new antiepileptic medications are available for the treatment of patients with seizure disorders. These drugs have demonstrated efficacy in animal models of epilepsy and in controlled clinical trials. Felbamate was licensed in 1993
O Devinsky et al.
Journal of child neurology, 9 Suppl 1, S33-S45 (1994-10-01)
After a 15-year hiatus, several new antiepileptic drugs have been approved or are under Food and Drug Administration investigation for use in the United States. This article reviews four of these new drugs--felbamate, gabapentin, lamotrigine, and vigabatrin. Although these drugs
J M Rho et al.
The Journal of pharmacology and experimental therapeutics, 280(3), 1383-1391 (1997-03-01)
Felbamate and meprobamate are structurally related propanediol dicarbamates that possess distinct pharmacological profiles. Felbamate is a minimally sedative, broad-spectrum anticonvulsant, whereas meprobamate is a strong sedative-anxiolytic agent. Previously, we reported that felbamate potentiates gamma-aminobutyric acid(A) (GABA(A)) receptor Cl- currents and
Huai-Ren Chang et al.
Journal of medicinal chemistry, 51(6), 1534-1545 (2008-03-04)
The antiepileptic effect of felbamate (FBM) is ascribable to gating modification of NMDA receptors. Using site-directed mutagenesis and electrophysiological studies, we found that single-point mutations of four pairs of homologous residues in the external vestibule of the receptor pore, namely
W M Brown et al.
Critical reviews in neurobiology, 12(3), 205-222 (1998-12-10)
Felbamate was launched in 1993 in the U.S. as a "new generation" antiepileptic drug (AED) with a unique mechanism of action. It proved efficacious in patients refractory to other AEDs and was particularly beneficial in children suffering from Lennox-Gastaut syndrome
B F Bourgeois
Seminars in pediatric neurology, 4(1), 3-8 (1997-03-01)
The development and release of felbamate is characterized by several relatively unique features. Felbamate was submitted to innovative and unconventional clinical trials. It was the first antiepileptic drug (AED) to be tested in a double-blind fashion in patients withdrawn from
S Grosso et al.
European journal of neurology, 15(9), 940-946 (2008-07-19)
To review our experience of the efficacy and tolerability of felbamate in children younger than 4 years. We used a retrospective chart review to identify 53 children with seizures who were younger than 4 years. Efficacy was evaluated based on
[New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
J L Herranz et al.
Neurologia (Barcelona, Spain), 9(9), 410-417 (1994-11-01)
Jian Yang et al.
Epilepsy research, 77(2-3), 157-164 (2007-11-06)
We have shown that a number of anticonvulsant drugs can reduce glutamate release at synapses in the rat entorhinal cortex (EC) in vitro. We have also shown that presynaptic NMDA receptors (NMDAr) tonically facilitate glutamate release at these synapses. In
D W Kaufman et al.
Epilepsia, 38(12), 1265-1269 (1998-05-13)
Felbamate (FBM) is a new antiepileptic drug (AED) that is often effective in seizure disorders refractory to other treatments; its use has been greatly restricted after cases of aplastic anemia were reported. To elucidate the putative association between FBM and
Antonino Germanò et al.
Journal of neurotrauma, 24(4), 732-744 (2007-04-19)
Increased levels of glutamate and aspartate have been detected after subarachnoid hemorrhage (SAH) that correlate with neurological status. The NMDA receptor antagonist felbamate (FBM; 2-phenyl-1,3-propanediol dicarbamate) is an anti-epileptic drug that elicits neuroprotective effects in different experimental models of hypoxia-ischemia.
Andrea Eugenio Cavanna et al.
Discovery medicine, 9(45), 138-144 (2010-03-03)
Anti-epileptic drugs (AEDs) have a variety of mechanisms of action which are reflected through different anticonvulsant activities and behavioral effects. Two categories of AEDs are considered based on psychotropic profile. The first group is characterized by potentiation of gamma-aminobutyric acid
Bartłomiej Barczyński et al.
European journal of pharmacology, 650(2-3), 550-555 (2010-11-03)
Experimental evidence indicates that bupropion hydrochloride, an antidepressant and a first-line smoking cessation aid, exerts dose-dependently anticonvulsant and convulsant effects. In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50)
1/2